DDInter79 DDInter1676
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label].
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Amlodipine {u} (Compound) resembles {v} (Compound) Nilvadipine
Amlodipine {u} (Compound) resembles {v} (Compound) Isradipine
Amlodipine {u} (Compound) treats {v} (Disease) hypertension
Amlodipine {u} (Compound) binds {v} (Gene) CACNA1B
Amlodipine {u} (Compound) upregulates {v} (Gene) ACLY
Amlodipine {u} (Compound) palliates {v} (Disease) coronary artery disease
Amlodipine {u} (Compound) is included by {v} (Pharmacologic Class) Dihydropyridines
Amlodipine {u} (Compound) downregulates {v} (Gene) NOLC1
Amlodipine {u} (Compound) causes {v} (Side Effect) Weight increased
Amlodipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Amlodipine (Compound) resembles Nilvadipine (Compound)
Amlodipine (Compound) resembles Isradipine (Compound)
Amlodipine (Compound) treats hypertension (Disease)
Amlodipine (Compound) binds CACNA1B (Gene)
Amlodipine (Compound) upregulates ACLY (Gene)
Amlodipine (Compound) palliates coronary artery disease (Disease)
Amlodipine (Compound) is included by Dihydropyridines (Pharmacologic Class)
Amlodipine (Compound) downregulates NOLC1 (Gene)
Amlodipine (Compound) causes Weight increased (Side Effect)
Amlodipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide